(Q43591191)

25 November 2017

title

Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information (English)

1 reference

25 November 2017

5

Irene L Andrulis

1 reference

25 November 2017

2

Anna M Mulligan

1 reference

25 November 2017

Linda P Feeley

1

1 reference

25 November 2017

Dushanthi Pinnaduwage

series ordinal

3

1 reference

25 November 2017

Shelley B Bull

series ordinal

4

1 reference

25 November 2017

publication date

20 September 2013

1 reference

25 November 2017

1 reference

25 November 2017

volume

27

1 reference

25 November 2017

issue

4

1 reference

25 November 2017

page(s)

554-561

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2013.153

25 November 2017

exact match

0 references

cites work

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Accumulation of p53 determined by immunohistochemistry as a prognostic marker in node negative breast cancer; analysis according to St Gallen consensus and intrinsic subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Histopathologic variables predict Oncotype DX recurrence score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

P53 protein accumulation in non-invasive lesions surrounding p53 mutation positive invasive breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Molecular classification and molecular forecasting of breast cancer: ready for clinical application?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Supervised risk predictor of breast cancer based on intrinsic subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

Tissue microarrays (TMAs) for high-throughput molecular pathology research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

A multimarker model to predict outcome in tamoxifen-treated breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

A risk index for early node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

7 January 2021

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

7 January 2021

Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

7 January 2021

Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

7 January 2021

Tissue microarrays for comparing molecular features with proliferation activity in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

7 January 2021

p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.153

7 January 2021

10.1038/MODPATHOL.2013.153

Identifiers

DOI

1 reference

Dimensions Publication ID

25 November 2017

1011384405

0 references

1 reference